SelectQuote, Inc. Reports First Quarter of Fiscal Year 2022 Results
SelectQuote, Inc. (NYSE: SLQT) reported a consolidated revenue of $159.9 million for Q1 FY2022, a 29% increase year-over-year. However, the company faced a net loss of $45.4 million, compared to a net income of $0.8 million in the previous year. The Senior segment saw revenues of $106.3 million (up 45% YoY), but Adjusted EBITDA was $(44.0) million, down from $12.1 million. The Auto & Home segment also declined 22% in revenue, highlighting mixed performance across sectors.
- Revenue of $106.3 million in the Senior segment, a 45% YoY increase.
- Medicare Advantage policies grew by 98% year-over-year.
- Secured an additional $200 million capital through a delayed draw term debt facility.
- Net loss of $45.4 million, a decline from previous net income.
- Adjusted EBITDA of $(44.0) million, significantly down from $12.1 million YoY.
- Auto & Home revenue decreased by 22% year-over-year.
First Quarter of Fiscal Year 2022 - Consolidated Earnings Highlights
-
Revenue of
, Up$159.9 million 29% Year-Over-Year -
Net Loss of
$45.4 million -
Adjusted EBITDA* of
$(44.0) million
First Quarter of Fiscal Year 2022 - Segment Highlights
Senior
-
Revenue of
, Up$106.3 million 45% Year-Over-Year -
Adjusted EBITDA* of
$(33.0) million -
Approved Medicare Advantage policies grew
98% Year-Over-Year
Life
-
Revenue of
, Up$49.8 million 16% Year-Over-Year -
Final expense premiums grew
72% Year-Over-Year
Auto & Home
-
Revenue of
, Down$7.5 million 22% Year-Over-Year -
Total Auto & Home premiums declined
22% Year-Over-Year
Chief Executive Officer
Chief Financial Officer
*See reconciliation from non-GAAP measure, Adjusted EBITDA, to net income (loss) on page 11.
Segment Results
We currently report on three segments: 1) Senior, 2) Life and 3) Auto & Home. The performance measures of the segments include total revenue and Adjusted EBITDA.* Costs of revenue, marketing and advertising, and technical development operating costs and expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, and technical development operating costs and expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA* is calculated as total revenue for the applicable segment less direct and allocated costs of revenue, marketing and advertising, technical development, and general and administrative operating costs and expenses, excluding depreciation and amortization expense; gain or loss on disposal of property, equipment, and software; share-based compensation expense; restructuring expenses; and non-recurring expenses such as severance payments and transaction costs.
Senior
Financial Results
The following table provides the financial results for the Senior segment for the periods presented:
|
Three Months Ended |
|
|
||||||||
(in thousands) |
2021 |
|
2020 |
|
% Change |
||||||
Revenue |
$ |
106,320 |
|
|
$ |
73,199 |
|
|
45 |
% |
|
Adjusted EBITDA* |
(32,971 |
) |
|
8,902 |
|
|
(470 |
)% |
|||
Adjusted EBITDA Margin* |
(31 |
)% |
|
12 |
% |
|
|
||||
Operating Metrics
Submitted Policies
Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to them to submit it to the insurance carrier partner. The applicant may have additional actions to take, such as providing additional information, before the application will be reviewed by the insurance carrier.
The following table shows the number of submitted policies for the periods presented:
|
Three Months Ended |
|
|
||||||
|
2021 |
|
2020 |
|
% Change |
||||
Medicare Advantage |
95,789 |
|
|
47,991 |
|
|
100 |
% |
|
Medicare Supplement |
1,812 |
|
|
7,276 |
|
|
(75 |
)% |
|
Dental, Vision and Hearing |
28,604 |
|
|
20,042 |
|
|
43 |
% |
|
Prescription Drug Plan |
873 |
|
|
2,425 |
|
|
(64 |
)% |
|
Other |
3,562 |
|
|
1,883 |
|
|
89 |
% |
|
Total |
130,640 |
|
|
79,617 |
|
|
64 |
% |
|
*See reconciliation from non-GAAP measure, Adjusted EBITDA, to net income (loss) on page 11.
Approved Policies
Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.
The following table shows the number of approved policies for the periods presented:
|
Three Months Ended |
|
|
||||||
|
2021 |
|
2020 |
|
% Change |
||||
Medicare Advantage |
84,116 |
|
|
42,473 |
|
|
98 |
% |
|
Medicare Supplement |
1,398 |
|
|
6,325 |
|
|
(78 |
)% |
|
Dental, Vision and Hearing |
22,223 |
|
|
16,239 |
|
|
37 |
% |
|
Prescription Drug Plan |
868 |
|
|
2,632 |
|
|
(67 |
)% |
|
Other |
2,880 |
|
|
1,824 |
|
|
58 |
% |
|
Total |
111,485 |
|
|
69,493 |
|
|
60 |
% |
|
Lifetime Value of Commissions per Approved Policy
Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.
The following table shows the lifetime value of commissions per approved policy for the periods presented:
|
Three Months Ended |
|
|
||||||||
(dollars per policy): |
2021 |
|
2020 |
|
% Change |
||||||
Medicare Advantage |
$ |
978 |
|
|
$ |
1,168 |
|
|
(16 |
)% |
|
Medicare Supplement |
1,439 |
|
|
1,274 |
|
|
13 |
% |
|||
Dental, Vision and Hearing |
152 |
|
|
168 |
|
|
(10 |
)% |
|||
Prescription Drug Plan |
310 |
|
|
240 |
|
|
29 |
% |
|||
Other |
111 |
|
|
135 |
|
|
(18 |
)% |
Per Unit Economics
Per unit economics represents total Medicare Advantage and Medicare Supplement commissions, other product commissions, other revenues, and costs associated with the Senior segment, each shown per number of approved Medicare Advantage and Medicare Supplement approved policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.
The Medicare Advantage and Medicare Supplement commission per MA/MS policy represents the lifetime value of commissions for policies sold in the period. Other commission per MA/MS policy represents the lifetime value of commissions for other products sold in the period, including dental, vision and hearing, prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Other per MA/MS policy represents the production bonuses, lead sales revenue from InsideResponse, and updated estimates of prior period variable consideration based on actual policy renewals in the current period. Total operating expenses per MA/MS policy represents all of the operating expenses within the Senior segment. The Revenue to customer acquisition cost (“CAC”) multiple represents total revenue per MA/MS policy as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.
The following table shows per unit economics for the periods presented. Based on the seasonality of the Senior segment and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per-MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles. These metrics are the basis on which management assesses the business:
|
Twelve Months Ended |
|
|
||||||||
(dollars per approved policy): |
2021 |
|
2020 |
|
% Change |
||||||
Medicare Advantage and Medicare Supplement approved policies |
526,212 |
|
|
271,199 |
|
|
94 |
% |
|||
Medicare Advantage and Medicare Supplement commission per MA/MS policy |
$ |
1,223 |
|
|
$ |
1,282 |
|
|
(5 |
)% |
|
Other commission per MA/MS policy |
37 |
|
|
48 |
|
|
(23 |
)% |
|||
Other per MA/MS policy |
188 |
|
|
171 |
|
|
10 |
% |
|||
Total revenue per MA/MS policy |
1,448 |
|
|
1,501 |
|
|
(4 |
)% |
|||
Total operating expenses per MA/MS policy |
(1,064) |
|
|
(924) |
|
|
15 |
% |
|||
Adjusted EBITDA per MA/MS policy* |
$ |
384 |
|
|
$ |
577 |
|
|
(33 |
)% |
|
Adjusted EBITDA Margin per MA/MS policy* |
27 |
% |
|
38 |
% |
|
(31 |
)% |
|||
Revenue/CAC multiple |
2.8X |
|
3.5X |
|
|
||||||
Life
Financial Results
The following table provides the financial results for the Life segment for the periods presented:
|
Three Months Ended |
|
|
||||||||
(in thousands) |
2021 |
|
2020 |
|
% Change |
||||||
Revenue |
$ |
49,826 |
|
|
$ |
42,823 |
|
|
16 |
% |
|
Adjusted EBITDA* |
4,698 |
|
|
10,477 |
|
|
(55 |
)% |
|||
Adjusted EBITDA Margin* |
9 |
% |
|
24 |
% |
|
|
||||
Operating Metrics
Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Core premiums include term life and permanent life insurance policies while ancillary premiums include various smaller products. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.
*See reconciliation from non-GAAP measure, Adjusted EBITDA, to net income (loss) on page 11.
The following table shows term and final expense premiums for the periods presented:
|
Three Months Ended |
|
|
||||||||
(in thousands) |
2021 |
|
2020 |
|
% Change |
||||||
Term Premiums |
$ |
15,510 |
|
|
$ |
18,855 |
|
|
(18 |
)% |
|
Final Expense Premiums |
34,052 |
|
|
19,817 |
|
|
72 |
% |
|||
Total |
$ |
49,562 |
|
|
$ |
38,672 |
|
|
28 |
% |
|
Auto & Home
Financial Results
The following table provides the financial results for the Auto & Home segment for the periods presented:
|
Three Months Ended |
|
|
||||||||
(in thousands) |
2021 |
|
2020 |
|
% Change |
||||||
Revenue |
$ |
7,469 |
|
|
$ |
9,538 |
|
|
(22 |
)% |
|
Adjusted EBITDA* |
1,374 |
|
|
3,616 |
|
|
(62 |
)% |
|||
Adjusted EBITDA Margin* |
18 |
% |
|
38 |
% |
|
|
||||
Operating Metrics
Auto & Home premium represents the total premium value of all new policies that were approved by our insurance carrier partners during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Auto & Home segment.
The following table shows premiums for the periods presented:
|
Three Months Ended |
|
|
||||||||
(in thousands): |
2021 |
|
2020 |
|
% Change |
||||||
Premiums |
$ |
13,258 |
|
|
$ |
16,900 |
|
|
(22 |
)% |
|
*See reconciliation from non-GAAP measure, Adjusted EBITDA, to net income (loss) on page 11.
Earnings Conference Call
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as income before interest expense, income tax expense, depreciation and amortization, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income. We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.
We believe that this non-GAAP financial measure helps identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude in the calculations of this non-GAAP financial measure. Accordingly, we believe that this financial measure provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.
Forward Looking Statement
This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.
There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: the ultimate duration and impact of the ongoing COVID-19 pandemic, our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the
About
Founded in 1985,
|
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(Unaudited) |
||||||||
(In thousands) |
||||||||
|
|
|
|
|||||
ASSETS |
|
|
|
|||||
CURRENT ASSETS: |
|
|
|
|||||
Cash and cash equivalents |
$ |
183,618 |
|
|
$ |
286,454 |
|
|
Accounts receivable |
96,673 |
|
|
113,375 |
|
|||
Commissions receivable-current |
155,482 |
|
|
89,120 |
|
|||
Other current assets |
7,917 |
|
|
4,486 |
|
|||
Total current assets |
443,690 |
|
|
493,435 |
|
|||
COMMISSIONS RECEIVABLE |
748,190 |
|
|
756,777 |
|
|||
PROPERTY AND EQUIPMENT—Net |
38,525 |
|
|
29,510 |
|
|||
SOFTWARE—Net |
14,264 |
|
|
12,611 |
|
|||
OPERATING LEASE RIGHT-OF-USE ASSETS |
30,547 |
|
|
31,414 |
|
|||
INTANGIBLE ASSETS—Net |
39,432 |
|
|
40,670 |
|
|||
|
73,732 |
|
|
68,019 |
|
|||
OTHER ASSETS |
1,362 |
|
|
1,436 |
|
|||
TOTAL ASSETS |
$ |
1,389,742 |
|
|
$ |
1,433,872 |
|
|
|
|
|
|
|||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|||||
CURRENT LIABILITIES: |
|
|
|
|||||
Accounts payable |
$ |
28,495 |
|
|
$ |
34,079 |
|
|
Accrued expenses |
22,836 |
|
|
20,676 |
|
|||
Accrued compensation and benefits |
43,648 |
|
|
40,909 |
|
|||
Operating lease liabilities—current |
5,355 |
|
|
5,289 |
|
|||
Current portion of long-term debt |
3,540 |
|
|
2,360 |
|
|||
Other current liabilities |
24,618 |
|
|
5,504 |
|
|||
Total current liabilities |
128,492 |
|
|
108,817 |
|
|||
LONG-TERM DEBT, less current portion |
458,652 |
|
|
459,043 |
|
|||
DEFERRED INCOME TAXES |
125,181 |
|
|
140,988 |
|
|||
OPERATING LEASE LIABILITIES |
37,186 |
|
|
38,392 |
|
|||
OTHER LIABILITIES |
6,446 |
|
|
11,743 |
|
|||
Total liabilities |
755,957 |
|
|
758,983 |
|
|||
|
|
|
|
|||||
COMMITMENTS AND CONTINGENCIES |
|
|
|
|||||
|
|
|
|
|||||
SHAREHOLDERS’ EQUITY: |
|
|
|
|||||
Common stock, |
1,639 |
|
|
1,635 |
|
|||
Additional paid-in capital |
549,034 |
|
|
544,771 |
|
|||
Retained earnings |
82,889 |
|
|
128,254 |
|
|||
Accumulated other comprehensive income |
223 |
|
|
229 |
|
|||
Total shareholders’ equity |
633,785 |
|
|
674,889 |
|
|||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ |
1,389,742 |
|
|
$ |
1,433,872 |
|
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) |
||||||||
(Unaudited) |
||||||||
(In thousands) |
||||||||
|
Three Months Ended |
|||||||
|
2021 |
|
2020 |
|||||
REVENUE: |
|
|
|
|||||
Commission |
$ |
134,651 |
|
|
$ |
106,545 |
|
|
Production bonus and other |
25,272 |
|
|
17,624 |
|
|||
Total revenue |
159,923 |
|
|
124,169 |
|
|||
|
|
|
|
|||||
OPERATING COSTS AND EXPENSES: |
|
|
|
|||||
Cost of revenue |
92,165 |
|
|
51,045 |
|
|||
Marketing and advertising |
90,677 |
|
|
49,800 |
|
|||
General and administrative |
23,392 |
|
|
12,202 |
|
|||
Technical development |
5,853 |
|
|
3,848 |
|
|||
Total operating costs and expenses |
212,087 |
|
|
116,895 |
|
|||
|
|
|
|
|||||
INCOME (LOSS) FROM OPERATIONS |
(52,164 |
) |
|
7,274 |
|
|||
|
|
|
|
|||||
INTEREST EXPENSE, NET |
(8,535 |
) |
|
(6,761 |
) |
|||
OTHER EXPENSE, NET |
(102 |
) |
|
(780 |
) |
|||
LOSS BEFORE INCOME TAX BENEFIT |
(60,801 |
) |
|
(267 |
) |
|||
INCOME TAX BENEFIT |
(15,436 |
) |
|
(1,104 |
) |
|||
|
|
|
|
|||||
NET INCOME (LOSS) |
$ |
(45,365 |
) |
|
$ |
837 |
|
|
|
|
|
|
|||||
NET INCOME (LOSS) PER SHARE: |
|
|
|
|||||
Basic |
$ |
(0.28 |
) |
|
$ |
0.01 |
|
|
Diluted |
$ |
(0.28 |
) |
|
$ |
0.01 |
|
|
|
|
|
|
|||||
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: |
|
|
|
|||||
Basic |
163,692 |
|
|
162,448 |
|
|||
Diluted |
163,692 |
|
|
165,192 |
|
|||
|
|
|
|
|||||
OTHER COMPREHENSIVE LOSS, NET OF TAX: |
|
|
|
|||||
Loss on cash flow hedge |
(6 |
) |
|
(257 |
) |
|||
OTHER COMPREHENSIVE LOSS |
(6 |
) |
|
(257 |
) |
|||
COMPREHENSIVE INCOME (LOSS) |
$ |
(45,371 |
) |
|
$ |
580 |
|
|
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(Unaudited) |
||||||||
(In thousands) |
||||||||
|
Three Months Ended |
|||||||
|
2021 |
|
2020 |
|||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|||||
Net income (loss) |
$ |
(45,365 |
) |
|
$ |
837 |
|
|
Adjustments to reconcile net income (loss) to net cash, cash equivalents, and restricted cash used in operating activities: |
|
|
|
|||||
Depreciation and amortization |
5,103 |
|
|
3,347 |
|
|||
Loss on disposal of property, equipment, and software |
350 |
|
|
82 |
|
|||
Share-based compensation expense |
2,215 |
|
|
924 |
|
|||
Deferred income taxes |
(15,807 |
) |
|
(1,214 |
) |
|||
Amortization of debt issuance costs and debt discount |
862 |
|
|
822 |
|
|||
Fair value adjustments to contingent earnout obligations |
— |
|
|
759 |
|
|||
Non-cash lease expense |
994 |
|
|
911 |
|
|||
Changes in operating assets and liabilities: |
|
|
|
|||||
Accounts receivable |
17,336 |
|
|
14,361 |
|
|||
Commissions receivable |
(57,775 |
) |
|
(45,942 |
) |
|||
Other assets |
(2,957 |
) |
|
1,790 |
|
|||
Accounts payable and accrued expenses |
(6,942 |
) |
|
(8,718 |
) |
|||
Operating lease liabilities |
(1,267 |
) |
|
(995 |
) |
|||
Other liabilities |
16,178 |
|
|
23,690 |
|
|||
Net cash used in operating activities |
(87,075 |
) |
|
(9,346 |
) |
|||
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|||||
Purchases of property and equipment |
(7,824 |
) |
|
(2,751 |
) |
|||
Purchases of software and capitalized software development costs |
(3,016 |
) |
|
(1,585 |
) |
|||
Acquisition of business |
(6,927 |
) |
|
121 |
|
|||
Net cash used in investing activities |
(17,767 |
) |
|
(4,215 |
) |
|||
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|||||
Payments on other debt |
(46 |
) |
|
(68 |
) |
|||
Proceeds from common stock options exercised and employee stock purchase plan |
2,194 |
|
|
309 |
|
|||
Payments of tax withholdings related to net share settlement of equity awards |
(142 |
) |
|
(2,509 |
) |
|||
Payments of costs incurred in connection with private placement |
— |
|
|
(1,771 |
) |
|||
Payments of costs incurred in connection with initial public offering |
— |
|
|
(3,899 |
) |
|||
Net cash provided by (used in) financing activities |
2,006 |
|
|
(7,938 |
) |
|||
|
(102,836 |
) |
|
(21,499 |
) |
|||
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—Beginning of period |
286,454 |
|
|
368,870 |
|
|||
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH—End of period |
$ |
183,618 |
|
|
$ |
347,371 |
|
|
||||||||||||||||||||
Adjusted EBITDA to Net Income Reconciliation |
||||||||||||||||||||
(Unaudited) |
||||||||||||||||||||
|
Three Months Ended |
|||||||||||||||||||
(in thousands) |
Senior |
|
Life |
|
Auto &
|
|
Corp &
|
|
Consolidated |
|||||||||||
Revenue |
$ |
106,320 |
|
|
$ |
49,826 |
|
|
$ |
7,469 |
|
|
$ |
(3,692 |
) |
|
$ |
159,923 |
|
|
Operating expenses |
(139,291 |
) |
|
(45,128 |
) |
|
(6,095 |
) |
|
(13,351 |
) |
|
(203,865 |
) |
||||||
Other expenses, net |
— |
|
|
— |
|
|
— |
|
|
(102 |
) |
|
(102 |
) |
||||||
Adjusted EBITDA |
(32,971 |
) |
|
4,698 |
|
|
1,374 |
|
|
(17,145 |
) |
|
(44,044 |
) |
||||||
Share-based compensation expense |
|
|
|
|
|
|
|
|
(2,215 |
) |
||||||||||
Non-recurring expenses |
|
|
|
|
|
|
|
|
(554 |
) |
||||||||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
(5,103 |
) |
||||||||||
Loss on disposal of property, equipment, and software |
|
|
|
|
|
|
|
|
(350 |
) |
||||||||||
Interest expense, net |
|
|
|
|
|
|
|
|
(8,535 |
) |
||||||||||
Income tax benefit |
|
|
|
|
|
|
|
|
15,436 |
|
||||||||||
Net loss |
|
|
|
|
|
|
|
|
$ |
(45,365 |
) |
|
Three Months Ended |
|||||||||||||||||||
(in thousands) |
Senior |
|
Life |
|
Auto &
|
|
Corp &
|
|
Consolidated |
|||||||||||
Revenue |
$ |
73,199 |
|
|
$ |
42,823 |
|
|
$ |
9,538 |
|
|
$ |
(1,391 |
) |
|
$ |
124,169 |
|
|
Operating expenses |
(64,297 |
) |
|
(32,346 |
) |
|
(5,922 |
) |
|
(9,518 |
) |
|
(112,083 |
) |
||||||
Other expenses, net |
— |
|
|
— |
|
|
— |
|
|
(21 |
) |
|
(21 |
) |
||||||
Adjusted EBITDA |
8,902 |
|
|
10,477 |
|
|
3,616 |
|
|
(10,930 |
) |
|
12,065 |
|
||||||
Share-based compensation expense |
|
|
|
|
|
|
|
|
(924 |
) |
||||||||||
Non-recurring expenses |
|
|
|
|
|
|
|
|
(438 |
) |
||||||||||
Fair value adjustments to contingent earnout obligations |
|
|
|
|
|
|
|
|
(759 |
) |
||||||||||
Restructuring expenses |
|
|
|
|
|
|
|
|
(21 |
) |
||||||||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
(3,347 |
) |
||||||||||
Loss on disposal of property, equipment, and software |
|
|
|
|
|
|
|
|
(82 |
) |
||||||||||
Interest expense, net |
|
|
|
|
|
|
|
|
(6,761 |
) |
||||||||||
Income tax benefit |
|
|
|
|
|
|
|
|
1,104 |
|
||||||||||
Net income |
|
|
|
|
|
|
|
|
$ |
837 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006279/en/
Investor Relations:
877-678-4083
investorrelations@selectquote.com
Media:
913-286-4931
matt.gunter@selectquote.com
913-653-4375
kelly.hale@selectquote.com
Source:
FAQ
What were SelectQuote's Q1 FY2022 earnings results?
How did the Senior segment perform in Q1 FY2022 for SLQT?
What is SelectQuote's outlook after Q1 FY2022 results?
What significant changes occurred in SelectQuote's Medicare Advantage policies?